Original paper
Effectiveness of subcutaneous tocilizumab in neuromyelitis optica spectrum disorders
Volume: 39, Pages: 101920 - 101920
Published: Apr 1, 2020
Abstract
Tocilizumab (TCZ), a humanized monoclonal antibody against the interleukin-6 receptor, is approved for treatment of rheumatoid arthritis and several other immune-mediated disorders. Off-label use of the intravenous formulation of tocilizumab for Neuromyelitis Optica Spectrum Disorder (NMOSD) decreased relapse rates in two small case series. However, treatment protocol that requires frequent intravenous infusions may adversely affect adherence to...
Paper Details
Title
Effectiveness of subcutaneous tocilizumab in neuromyelitis optica spectrum disorders
Published Date
Apr 1, 2020
Volume
39
Pages
101920 - 101920
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History